Solomon: Transforming moment for the company
CEO calls the recommendation of the Zealand Pharma-developed diabetes drug Lyxumia a transforming moment. He also says that the Danish company has a “good” royalty-deal in place with its partner Sanofi and reveals the company’s next Lyxumia.
by Stefan Singh Kailay
David Solomon, CEO of Zealand Pharma, was a happy man, when Medwatch spoke to him moments after it was announced that the company’s diabetes drug Lyxumia had been recommended for approval by an EMA medical committee.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Zealand’s diabetes-hope recommended for approval
For abonnenter
Zealand initiating new diabetes/obesity study
For abonnenter
CEO: Zealand is changing
For abonnenter
.jpg&w=384&q=75){kind=logo}
